[Update on the role of levofloxacin in the management of acute community-acquired pneumonia].
THE EFFICACY OF LEVOFLOXACIN: In treating community-acquired pneumonia (CAP) has been assessed during 5 large clinical trials (including 4 controlled randomized trials). 1067 PATIENTS HAVE BEEN TREATED BY LEVOFLOXACIN: And 645 by a comparator. Success rates were identical between levofloxacin and comparator ranging from 70.6% to 84.2% for levofloxacin treated patients, and from 75% to 85.7% for comparators treated patients. 549 PRESUMED OR PROVED PNEUMOCOCCAL PNEUMONIA: Have been treated by levofloxacin with a success rate ranging from 83% to 100%, and 379 have been treated by a comparator with a success rate ranging from 90% to 95%. Success rates for the 310 pneumococcal-documented infections, including 96 bacteraemia, were identical between levofloxacin and comparator. The severity of the patients ranged between studies from moderate to severe. PROOFS COMING FROM THOSE CLINICAL TRIALS: Show the efficiency of levofloxacin in the treatment of moderate to severe community acquired pneumonia in adults, and in the treatment of presumed or proved pneumonia, with or without bacteraemia.
Bru
Jean-Pierre
JP
Service d'Infectiologie, Centre Hospitalier, 74000 Annecy.
D000208:Acute Disease; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000209:etiology / Q000517:prevention & control; D017714:Community-Acquired Infections / Q000188:drug therapy; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000627:therapeutic use*; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin